Bronchopulmonary Dysplasia Market

DelveInsight’s ‘Bronchopulmonary Dysplasia-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. 

 

The Bronchopulmonary Dysplasia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Bronchopulmonary Dysplasia market size from 2019 to 2032. The Report also covers current Bronchopulmonary Dysplasia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Bronchopulmonary Dysplasia Disease Understanding and Treatment Algorithm

Bronchopulmonary Dysplasia Overview

Bronchopulmonary dysplasia (Bronchopulmonary Dysplasia) is a chronic respiratory disease that often occurs in low-weight or premature infants who have received supplemental oxygen or have spent long periods on a breathing machine (mechanical ventilation), such as infants with acute respiratory distress syndrome. Bronchopulmonary Dysplasia also occurs in older infants who experience abnormal lung development or those that have an antenatal infection or placental abnormalities (like preeclampsia) or chorioamnionitis. Babies are not born with Bronchopulmonary Dysplasia, also referred to as chronic lung disease of prematurity, it is associated with how a baby’s lung tissue develops.

 

The risk of developing Bronchopulmonary Dysplasia increases the earlier a baby is born and the lower the birth weight. Affected infants have rapid, labored breathing, tachypnea, cyanosis, feeding difficulties, and recurrent lung infection. The pathogenesis of Bronchopulmonary Dysplasia remains complex and poorly understood. It results from various factors that injure small airways and can interfere with alveolarization, leading to alveolar simplification with a reduction in the overall surface area for gas exchange. The developing pulmonary microvasculature is also injured. Damage to the lung during a critical stage of lung growth results in clinically significant pulmonary dysfunction

 

Bronchopulmonary Dysplasia is divided into three severity grades (mild, moderate, or severe) based on respiratory support needs at 36 weeks postmenstrual age (PMA). The exact, underlying mechanisms that cause classic or new Bronchopulmonary Dysplasia are complex and not fully understood. The causes of Bronchopulmonary Dysplasia in one infant may be different from the causes in another. Most likely, multiple different environmental and genetic factors all play a role in the development of the disorder.

 

The cases of Bronchopulmonary Dysplasia have been increasing, most likely because of modern advances in medicine, which have enabled doctors to keep more low birth weight, premature babies alive than in the past. 

 

Bronchopulmonary Dysplasia Diagnosis 

Infants with Bronchopulmonary Dysplasia show substantial heterogeneity in clinical presentation and long-term outcomes. The manner and precision with which Bronchopulmonary Dysplasia is defined have far-reaching consequences for translational and clinical research.

 

Diagnosis is done based upon identification of characteristic symptoms, detailed patient history, thorough clinical evaluation, and a variety of specialized tests, including blood tests, chest x-rays, and echocardiograms. Many infants now, diagnosed with Bronchopulmonary Dysplasia, are born at an earlier gestational age than before. These cases are sometimes referred to as “new Bronchopulmonary Dysplasia.” They generally have less inflammation and scarring than classic Bronchopulmonary Dysplasia.

Continued in the report…..

 

Bronchopulmonary Dysplasia Treatment 

To date, there is no specific cure for Bronchopulmonary Dysplasia, and the focus is on minimizing lung damage and providing support for the lung to heal and grow. Treatment includes mechanical ventilation along with supplemental oxygen to improve lung capacity and help them breathe. Antenatal steroid treatment before preterm birth and early treatment with surfactant reduce the need for high levels of respiratory support after birth. Infants are also given different medications, including bronchodilators, diuretics, antibiotics, and steroids to reduce lung inflammation and congestion. Proper nutrition management ensures healthy lung development.

 

Current strategies for the prevention of Bronchopulmonary Dysplasia can broadly be divided into antenatal pharmacologic interventions such as maternal progesterone and antenatal steroids and postnatal pharmacologic interventions.

 

Though Bronchopulmonary Dysplasia management has improved with the advent of new and effective perinatal strategies, it still is the most common complication associated with prematurity and the major cause of respiratory morbidities. Its prevention and management remain a major challenge for neonatologists, especially with the increasing survival of extremely premature infants.

Bronchopulmonary Dysplasia Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Bronchopulmonary Dysplasia, weight-specific cases of bronchopulmonary dysplasia, severity-specific cases of bronchopulmonary dysplasia scenario of Bronchopulmonary Dysplasia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total incident cases of Bronchopulmonary Dysplasia in the 7MM were found to be 17,058 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019–2032). The incident cases of BPD are derived from preterm population of <28 weeks.
  • Among 7MM, the United States has the highest incident cases of Bronchopulmonary Dysplasia with 13,222 cases in 2021. 
  • Assessments as per DelveInsight’s analysts show that the majority of cases of Bronchopulmonary Dysplasia are in ≤750 g birth weight preterm infants as compared to other birth-weight groups. In the United States, there were 5,203 cases of Bronchopulmonary Dysplasia in ≤750 g birth weight group preterm infants followed by 751-1000 g (5,022 cases), 1001-1250 g (2,290 cases), and ≥1250 g (706 cases) in 2021. These cases are expected to increase by 2032.
  • The severity‚Äźspecific data reveal the highest number of preterm infants are having mild Bronchopulmonary Dysplasia.
  • In the United States, there were a total of 5,210, 5,192, and 2,820 severity-specific cases of mild, moderate, and severe Bronchopulmonary Dysplasia respectively, in 2021. As per DelveInsight’s analysts, the severity-specific cases of Bronchopulmonary Dysplasia will increase by 2032.
  • In EU-5, Germany has the highest number of cases of Bronchopulmonary Dysplasia with 944 cases in 2021, followed by France with 931 cases and the United Kingdom with 735 cases. While Italy has the least number of cases with 386 in 2021.
  • In 2021, Japan had 452 incident cases of Bronchopulmonary Dysplasia.

Country-Wise Bronchopulmonary Dysplasia Epidemiology 

The epidemiology segment also provides the Bronchopulmonary Dysplasia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Bronchopulmonary Dysplasia Drug Chapters

The drug chapter segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of Bronchopulmonary Dysplasia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Bronchopulmonary Dysplasia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Bronchopulmonary Dysplasia Emerging Drugs 

 

OHB-607: Takeda/Oak Hill Bio

Oak Hill’s lead therapeutic candidate, OHB-607 (formerly TAK-607), is a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1), the natural version of which is a key driver of fetal growth and development in-utero, and its binding protein, IGFBP-3. IGF-1 plays an important role in the development of the fetus. OHB-607 has been evaluated in both preclinical and clinical studies to treat Bronchopulmonary Dysplasia. A Phase II clinical trial showed a statistically significant shift toward milder Bronchopulmonary Dysplasia and a positive trend in reducing intraventricular hemorrhage (pre-specified secondary endpoints), with no significant safety signal observed. The company plans to restart the Phase IIb trial to evaluate 0HB-607 in Bronchopulmonary Dysplasia patients.

Products detail in the report…

 

CHF5633: Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici is evaluating CHF5633 to treat Bronchopulmonary Dysplasia. It is the first fully synthetic surfactant enriched by peptide analogs of two human surfactant proteins. The drug is in the early clinical stage of development for Bronchopulmonary Dysplasia. Through the clinical success of porcine surfactant (Poractant alfa, Curosurf) in treating neonatal respiratory distress syndrome (RDS), Chiesi has established an impressive platform in neonatology. CHF5633 completed its evaluation in Phase II compared to Curosurf in treating preterm neonates with RDS. The drug is presently being evaluated in early clinical-stage development to treat BPD.

Products detail in the report…

List of products to be continued in the report…

Bronchopulmonary Dysplasia Market Outlook

While prenatal steroids, surfactants, ventilators, and improved resuscitation protocols have increased the survival rate of premature infants, there has been little progress in protecting their not fully developed organs from the trauma of life-saving measures at birth, including supplemental oxygen and breathing machines.

 

The pipeline for Bronchopulmonary Dysplasia is currently limited, consisting of only one key asset, i.e., OHB607 (mecasermin rinfabate), an intravenous infusion being developed by Oak Hill. Other assets in development include Pneumostem (Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells) being developed by Medipost, AT-100 (Airway Therapeutics), AVR-48 (AyuVis), and CHF5633 (Chiesi Farmaceutici). 

 

Oak Hill Bio plans to restart the Phase IIb study of the drug to treat Bronchopulmonary Dysplasia. The company states that the drug has the potential to be the first breakthrough in more than 30 years to improve outcomes for preterm infants. It will be the first-ever therapy to enter the US, EU, and JP market for the treatment of Bronchopulmonary Dysplasia and might bring a significant boost in the Bronchopulmonary Dysplasia market.

 

With all other drugs in the early stages of development, until now, OHB607 seems to be the most promising candidate in the clinical pipeline of Bronchopulmonary Dysplasia. The market is expected to react positively to OHB607, aiding it in solidifying its position as a leading therapy for this indication, as no other therapy has been able to pave its way to approval yet. We believe the expected approval of emerging therapy and the improving understanding of the disease due to advancing techniques will allow the market to rise at a significant rate.

 

According to DelveInsight, Bronchopulmonary Dysplasia 7MM is expected to change in the study period 2019–2032.

 

Key Findings

  • The market size of Bronchopulmonary Dysplasia in seven major markets was USD  0.028 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 66.2% for the study period (2019–2032)
  • The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the incident population of Bronchopulmonary Dysplasia.
  • Upcoming therapies such as Oak Hill Bio’s (OHB607) have the potential to create a significant positive shift in the Bronchopulmonary Dysplasia market size.
  • The United States accounts for the largest market size of Bronchopulmonary Dysplasia, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
  • Among the EU5 countries, Germany and France had the highest market size with USD 0.002 million in 2021.

 

The United States Market Outlook

This section provides the total Bronchopulmonary Dysplasia market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Bronchopulmonary Dysplasia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total Bronchopulmonary Dysplasia market size and market size by therapies in Japan are provided.

Bronchopulmonary Dysplasia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Bronchopulmonary Dysplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bronchopulmonary Dysplasia Development Activities 

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Bronchopulmonary Dysplasia emerging therapies. 

Reimbursement Scenario in Bronchopulmonary Dysplasia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

Competitive Intelligence Analysis 

We perform competitively and market Intelligence analysis of the Bronchopulmonary Dysplasia market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Bronchopulmonary Dysplasia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Bronchopulmonary Dysplasia epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bronchopulmonary Dysplasia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Bronchopulmonary Dysplasia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Bronchopulmonary Dysplasia market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Bronchopulmonary Dysplasia market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bronchopulmonary Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Bronchopulmonary Dysplasia. The launch of emerging therapies will significantly impact the Bronchopulmonary Dysplasia market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bronchopulmonary Dysplasia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Bronchopulmonary Dysplasia Pipeline Analysis
  • Bronchopulmonary Dysplasia Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Bronchopulmonary Dysplasia Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage 
  • Bronchopulmonary Dysplasia Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Bronchopulmonary Dysplasia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Bronchopulmonary Dysplasia market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Bronchopulmonary Dysplasia total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Bronchopulmonary Dysplasia market size during the forecast period (2022–2032)?
  • At what CAGR, the Bronchopulmonary Dysplasia market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Bronchopulmonary Dysplasia market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Bronchopulmonary Dysplasia market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Bronchopulmonary Dysplasia?
  • What is the historical Bronchopulmonary Dysplasia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Bronchopulmonary Dysplasia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Bronchopulmonary Dysplasia?
  • Out of the above-mentioned countries, which country would have the highest incidence population of Bronchopulmonary Dysplasia during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Bronchopulmonary Dysplasia along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Bronchopulmonary Dysplasia in the US and Europe?
  • What are the Bronchopulmonary Dysplasia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Bronchopulmonary Dysplasia?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Bronchopulmonary Dysplasia?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchopulmonary Dysplasia therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Bronchopulmonary Dysplasia and their status?
  • What are the key designations that have been granted for the emerging therapies for Bronchopulmonary Dysplasia?
  • What are the 7MM historical and forecasted market of Bronchopulmonary Dysplasia?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Bronchopulmonary Dysplasia.
  • To understand the future market competition in the Bronchopulmonary Dysplasia market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Bronchopulmonary Dysplasia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Bronchopulmonary Dysplasia market.
  • To understand the future market competition in the Bronchopulmonary Dysplasia market.

1. Key Insights

2. Report Introduction

3. Bronchopulmonary Dysplasia Market Overview at a Glance

3.1. Market Share (%) Distribution of Bronchopulmonary Dysplasia by Therapies in 2019

3.2. Market Share (%) Distribution of Bronchopulmonary Dysplasia by Therapies in 2032

4. Bronchopulmonary Dysplasia Market: Future Perspective

5. Executive Summary of Bronchopulmonary Dysplasia

6. Key Events

7. Disease Background and Overview

7.1. Introduction of Bronchopulmonary Dysplasia

7.2. Classification of Bronchopulmonary Dysplasia

7.3. Signs and Symptoms of Bronchopulmonary Dysplasia

7.4. Etiology associated with Bronchopulmonary Dysplasia

7.5. Pathophysiology of Bronchopulmonary Dysplasia

7.6. Diagnosis of Bronchopulmonary Dysplasia

7.7. Biomarkers for Bronchopulmonary Dysplasia

7.8. Treatment and Management of Bronchopulmonary Dysplasia

7.8.1. Treatment Guidelines

7.8.1.1. European Respiratory Society Guideline on Long-term Management of Children with Bronchopulmonary Dysplasia

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.3.1. The United States

8.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.3.3. Japan

8.4. Total Incident Cases of Bronchopulmonary Dysplasia in the 7MM

8.5. The United States

8.5.1. Incident Cases of Bronchopulmonary Dysplasia in the United States

8.5.2. Weight-specific Cases of Bronchopulmonary Dysplasia in the United States

8.5.3. Severity-specific Cases of Bronchopulmonary Dysplasia in the United States

8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.6.1. Germany

8.6.1.1. Incident Cases of Bronchopulmonary Dysplasia in Germany

8.6.1.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Germany

8.6.1.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Germany

8.6.2. France

8.6.2.1. Incident Cases of Bronchopulmonary Dysplasia in France

8.6.2.2. Weight-specific Cases of Bronchopulmonary Dysplasia in France

8.6.2.3. Severity-specific Cases of Bronchopulmonary Dysplasia in France

8.6.3. Italy

8.6.3.1. Incident Cases of Bronchopulmonary Dysplasia in Italy

8.6.3.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Italy

8.6.3.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Italy

8.6.4. Spain

8.6.4.1. Incident Cases of Bronchopulmonary Dysplasia in Spain

8.6.4.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Spain

8.6.4.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Spain

8.6.5. The United Kingdom

8.6.5.1. Incident Cases of Bronchopulmonary Dysplasia in the UK

8.6.5.2. Weight-specific Cases of Bronchopulmonary Dysplasia in the UK

8.6.5.3. Severity-specific Cases of Bronchopulmonary Dysplasia in the UK

8.7. Japan

8.7.1. Incident Cases of Bronchopulmonary Dysplasia in Japan

8.7.2. Weight-specific Cases of Bronchopulmonary Dysplasia in Japan

8.7.3. Severity-specific Cases of Bronchopulmonary Dysplasia in Japan

9. Patient Journey

10. Emerging Drugs

10.1. Key Competitors

10.2. OHB-607/TAK-607/SHP607 (Mecasermin Rinfabate): Takeda/Oak Hill Bio

10.2.1. Product Description

10.2.2. Other Development Activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.2.7. Analysts’ Views

10.3. CHF5633: Chiesi Farmaceutici S.p.A.

10.3.1. Product Description

10.3.2. Clinical Development

10.3.3. Clinical Trials Information

10.3.4. Safety and Efficacy

10.3.5. Product Profile

10.3.6. Analysts’ Views

10.4. Pneumostem: Medipost

10.4.1. Product Description

10.4.2. Other Development Activities

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.4.7. Analysts’ Views

10.5. AT-100: Airway Therapeutic

10.5.1. Product Description

10.5.2. Other Development Activities

10.5.3. Clinical Development

10.5.4. Clinical Trials Information

10.5.5. Product Profile

10.5.6. Analysts’ Views

10.6. Inhaled Nitric Oxide: Mallinckrodt/AdventHealth

10.6.1. Product Description

10.6.2. Clinical Development

10.6.3. Clinical Trials Information

10.6.4. Product Profile

10.6.5. Analysts’ Views

11. Bronchopulmonary Dysplasia: Seven Major Market Analysis

11.1. Key Findings

11.2. Methodology of Bronchopulmonary Dysplasia Market

11.3. Market Outlook

11.4. Potential of Current and Emerging Therapies

11.5. Key Market Forecast Assumptions

11.6. Market Size of Bronchopulmonary Dysplasia in the 7MM

11.7. Market Size of Bronchopulmonary Dysplasia by Therapies in the 7MM

11.8. Market Size of Bronchopulmonary Dysplasia in the United States

11.8.1. Total Market Size of Bronchopulmonary Dysplasia

11.8.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.9. Market Size of Bronchopulmonary Dysplasia in the EU-5

11.9.1. Germany

11.9.1.1. Total Market Size of Bronchopulmonary Dysplasia

11.9.1.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.9.2. France

11.9.2.1. Total Market Size of Bronchopulmonary Dysplasia

11.9.2.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.9.3. Italy

11.9.3.1. Total Market Size of Bronchopulmonary Dysplasia

11.9.3.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.9.4. Spain

11.9.4.1. Total Market Size of Bronchopulmonary Dysplasia

11.9.4.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.9.5. The United Kingdom

11.9.5.1. Total Market Size of Bronchopulmonary Dysplasia

11.9.5.2. Market Size of Bronchopulmonary Dysplasia by Therapies

11.10. Market Size of Bronchopulmonary Dysplasia in Japan

11.10.1. Total Market Size of Bronchopulmonary Dysplasia

11.10.2. Market Size of Bronchopulmonary Dysplasia by Therapies

12. Key Opinion Leaders’ Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Reimbursement and Market Access

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Bronchopulmonary Dysplasia Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Treatment of Bronchopulmonary Dysplasia

Table 4: Incident Cases of Bronchopulmonary Dysplasia in the 7MM (2019–2032)

Table 5: Incident Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Table 6: Weight-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Table 7: Severity-specific Cases of Bronchopulmonary Dysplasia in the United States (2019–2032)

Table 8: Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 9: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 10: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Table 11: Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 12: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 13: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Table 14: Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 15: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 16: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Table 17: Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 18: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 19: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Table 20: Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 21: Weight-specific Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 22: Severity-specific Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Table 23: Incident Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Table 24: Weight-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Table 25: Severity-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Table 26: Comparison of Emerging Drugs Under Development

Table 27: OHB-607 (SHP607/Mecasermin Rinfabate), Clinical Trial Description, 2022

Table 28: CHF5633, Clinical Trial Description, 2022

Table 29: Pneumostem, Clinical Trial Description, 2022

Table 30: AT-100, Clinical Trial Description, 2022

Table 31: Inhaled Nitric Oxide, Clinical Trial Description, 2022

Table 32: Key Market Forecast Assumptions for OHB607

Table 33: Market Size of Bronchopulmonary Dysplasia in the 7MM, USD Millions (2019–2032)

Table 34: Market Size of Bronchopulmonary Dysplasia by Therapies in the 7MM, in USD Million (2019–2032)

Table 35: Market Size of Bronchopulmonary Dysplasia in the United States, USD Millions (2019–2032)

Table 36: Market Size of Bronchopulmonary Dysplasia by Therapies in the United States, in USD Million (2019–2032)

Table 37: Market Size of Bronchopulmonary Dysplasia in the EU-5, USD Millions (2019–2032)

Table 38: Market Size of Bronchopulmonary Dysplasia by Therapies in the EU-5, in USD Million (2019–2032)

Table 39: Market Size of Bronchopulmonary Dysplasia in Germany, USD Millions (2019–2032)

Table 40: Market Size of Bronchopulmonary Dysplasia by Therapies in Germany, in USD Million (2019–2032)

Table 41: Market Size of Bronchopulmonary Dysplasia in France, USD Millions (2019–2032)

Table 42: Market Size of Bronchopulmonary Dysplasia by Therapies in France, in USD Million (2019–2032)

Table 43: Market Size of Bronchopulmonary Dysplasia in Italy, USD Millions (2019–2032)

Table 44: Market Size of Bronchopulmonary Dysplasia by Therapies in Italy, in USD Million (2019–2032)

Table 45: Market Size of Bronchopulmonary Dysplasia in Spain, USD Millions (2019–2032)

Table 46: Market Size of Bronchopulmonary Dysplasia by Therapies in Spain, in USD Million (2019–2032)

Table 47: Market Size of Bronchopulmonary Dysplasia in the UK, USD Millions (2019–2032)

Table 48: Market Size of Bronchopulmonary Dysplasia by Therapies in the UK, in USD Million (2019–2032)

Table 49: Market Size of Bronchopulmonary Dysplasia in Japan, USD Millions (2019–2032)

Table 50: Market Size of Bronchopulmonary Dysplasia by Therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: Factors influencing Bronchopulmonary Dysplasia

Figure 2: Classification of BPD

Figure 3: Signs and Symptoms of Bronchopulmonary Dysplasia

Figure 4: Risk Factors of BPD

Figure 5: Stages of Lung Development

Figure 6: Pathogenesis of BPD

Figure 7: Diagnosis of BPD

Figure 8: Biomarkers Associated with BPD

Figure 9: Incident Cases of Bronchopulmonary Dysplasia in the 7MM (2019–2032)

Figure 10: Incident Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 11: Weight-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 12: Severity-specific Cases of Bronchopulmonary Dysplasia in the US (2019–2032)

Figure 13: Incident Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 14: Weight-specific Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 15: Severity-specific Cases of Bronchopulmonary Dysplasia in Germany (2019–2032)

Figure 16: Incident Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Figure 17: Weight-specific Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Figure 18: Severity-specific Cases of Bronchopulmonary Dysplasia in France (2019–2032)

Figure 19: Incident Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 20: Weight-specific Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 21: Severity-specific Cases of Bronchopulmonary Dysplasia in Italy (2019–2032)

Figure 22: Incident Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 23: Weight-specific Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 24: Severity-specific Cases of Bronchopulmonary Dysplasia in Spain (2019–2032)

Figure 25: Incident Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 26: Weight-specific Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 27: Severity-specific Cases of Bronchopulmonary Dysplasia in the UK (2019–2032)

Figure 28: Incident Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 29: Weight-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 30: Severity-specific Cases of Bronchopulmonary Dysplasia in Japan (2019–2032)

Figure 31: Patient Journey

Figure 32: Market Size of Bronchopulmonary Dysplasia in the 7MM, USD Millions (2019–2032)

Figure 33: Market Size of Bronchopulmonary Dysplasia by Therapies in the 7MM, in USD Million (2019–2032)

Figure 34: Market Size of Bronchopulmonary Dysplasia in the United States, USD Millions (2019–2032)

Figure 35: Market Size of Bronchopulmonary Dysplasia by Therapies in the United States, in USD Million (2019–2032)

Figure 36: Market Size of Bronchopulmonary Dysplasia in Germany, USD Millions (2019–2032)

Figure 37: Market Size of Bronchopulmonary Dysplasia by Therapies in Germany, in USD Million (2019–2032)

Figure 38: Market Size of Bronchopulmonary Dysplasia in France, USD Millions (2019–2032)

Figure 39: Market Size of Bronchopulmonary Dysplasia by Therapies in France, in USD Million (2019–2032)

Figure 40: Market Size of Bronchopulmonary Dysplasia in Italy, USD Millions (2019–2032)

Figure 41: Market Size of Bronchopulmonary Dysplasia by Therapies in Italy, in USD Million (2019–2032)

Figure 42: Market Size of Bronchopulmonary Dysplasia in Spain, USD Millions (2019–2032)

Figure 43: Market Size of Bronchopulmonary Dysplasia by Therapies in Spain, in USD Million (2019–2032)

Figure 44: Market Size of Bronchopulmonary Dysplasia in the UK, USD Millions (2019–2032)

Figure 45: Market Size of Bronchopulmonary Dysplasia by Therapies in the UK, in USD Million (2019–2032)

Figure 46: Market Size of Bronchopulmonary Dysplasia in Japan, USD Millions (2019–2032)

Figure 47: Market Size of Bronchopulmonary Dysplasia by Therapies in Japan, in USD Million (2019–2032)

Figure 48: Market Drivers

Figure 49: Market Barriers

Figure 50: SWOT Analysis

Figure 51: Unmet Needs

Takeda
Oak Hill Bio
Chiesi Farmaceutici S.p.A.
Medipost
Airway Therapeutic
Mallinckrodt
AdventHealth

 

Forward to Friend

Need A Quote